Provigil Antitrust Cert. Bid Doomed By Inability To ID Class
A Pennsylvania federal judge on Wednesday explained that his recent refusal to let consumers and health plans go forward with class antitrust pay-for-delay claims against Cephalon Inc. and four generic drugmakers...To view the full article, register now.
Already a subscriber? Click here to view full article